For instance, entinostat (formally MS-275, Syndax Pharmaceuticals, Inc, Waltham, MA) is an ideal example of class I HDAC inhibitor which possesses the ability to reduce the proliferation of cancer cells and tumor xenografts in various cancer types while exhibiting mild toxicity to normal cells (129). This evidence concerns the gene HDAC9 and cancer.